Standout Papers

Global burden of NAFLD and NASH... 1999 2026 2008 2017 3.7k
  1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention (2017)
    Zobair M. Younossi, Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
  2. Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome (2003)
    Giulio Marchesini, Elisabetta Bugianesi et al. Hepatology
  3. Nonalcoholic Fatty Liver Disease (2001)
    Giulio Marchesini, Mara Brizi et al. Diabetes
  4. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis (2018)
    Zobair M. Younossi, Frank Tacke et al. Hepatology
  5. Association of nonalcoholic fatty liver disease with insulin resistance (1999)
    Giulio Marchesini, Mara Brizi et al. The American Journal of Medicine
  6. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma (2002)
    Elisabetta Bugianesi, Nicola Leone et al. Gastroenterology
  7. Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease * (2005)
    Elisabetta Bugianesi, Arthur J. McCullough et al. Hepatology
  8. Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease (2013)
    Melania Gaggini, Mariangela Morelli et al. Nutrients
  9. Nonalcoholic fatty liver disease (2015)
    Elizabeth M. Brunt, Vincent Wai‐Sun Wong et al. Nature Reviews Disease Primers
  10. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates (2018)
    Zobair M. Younossi, Maria Stepanova et al. Clinical Gastroenterology and Hepatology
  11. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms (2005)
    Elisabetta Bugianesi, Amalia Gastaldelli et al. Diabetologia
  12. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016)
    Stuart McPherson, Timothy Hardy et al. The American Journal of Gastroenterology
  13. A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease (2005)
    Elisabetta Bugianesi, E. Gentilcore et al. The American Journal of Gastroenterology
  14. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis (2015)
    Andrea Marengo, Chiara Rosso et al. Annual Review of Medicine
  15. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes (2008)
    Anna Ludovica Fracanzani, Luca Valenti et al. Hepatology
  16. Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease† (2010)
    Luca Valenti, Ahmad Al‐Serri et al. Hepatology
  17. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) (2024)
    Frank Tacke, Paul Horn et al. Journal of Hepatology
  18. Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (2013)
    Paul Angulo, Elisabetta Bugianesi et al. Gastroenterology
  19. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease (2021)
    Fasiha Kanwal, Jay H. Shubrook et al. Gastroenterology
  20. Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance (2017)
    Melania Gaggini, Fabrizia Carli et al. Hepatology
  21. Global epidemiology of cirrhosis — aetiology, trends and predictions (2023)
    Daniel Q. Huang, Norah A. Terrault et al. Nature Reviews Gastroenterology & Hepatology
  22. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis (2024)
    Rohit Loomba, Mark L. Hartman et al. New England Journal of Medicine
  23. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation (2019)
    Fei Chen, Saeed Esmaili et al. Hepatology
  24. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024)
    Arun J. Sanyal, Pierre Bédossa et al. New England Journal of Medicine
  25. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight (2022)
    Mohammed Eslam, Hashem B. El‐Serag et al. Nature Reviews Gastroenterology & Hepatology
  26. Current therapies and new developments in NASH (2022)
    Jean‐François Dufour, Quentin M. Anstee et al. Gut
  27. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (2025)
    Danny Issa, Philip N. Newsome et al. New England Journal of Medicine
  28. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures (2023)
    Olivier Govaere, Leigh Alexander et al. Nature Metabolism
  29. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial (2024)
    Philip N. Newsome, Arun J. Sanyal et al. Alimentary Pharmacology & Therapeutics
  30. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary (2024)
    Frank Tacke, Paul Horn et al. Diabetologia

Immediate Impact

9 by Nobel laureates 6 from Science/Nature 351 standout
Sub-graph 1 of 13

Citing Papers

Acquisition of epithelial plasticity in human chronic liver disease
2024 StandoutNature
Steatotic liver disease
2024 Standout
51 intermediate papers

Works of Elisabetta Bugianesi being referenced

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
Global epidemiology of cirrhosis — aetiology, trends and predictions
2023 Standout
and 38 more

Author Peers

Author Last Decade Papers Cites
Elisabetta Bugianesi 26731 10190 12431 282 31.7k
Arthur J. McCullough 27432 11779 11652 292 34.4k
Stephen A. Harrison 24793 11080 11597 387 30.7k
Brent A. Neuschwander‐Tetri 24212 9883 10995 186 29.7k
Christopher P. Day 22363 9924 9677 183 30.3k
Kenneth Cusi 22938 7419 14358 213 31.9k
Naga Chalasani 25932 13934 9759 485 35.8k
Quentin M. Anstee 18861 8645 7626 247 22.8k
Joel E. Lavine 23582 9615 11524 144 27.6k
Geoffrey C. Farrell 19440 9801 6780 213 25.5k
Giovanni Targher 27937 8537 16995 548 42.4k

All Works

Loading papers...

Rankless by CCL
2026